A Phase I/II trial of olaparib palbociclib and fulvestrant in patients with BRCA mutation-associated hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer
Enrolling By Invitation
18 years - 99 years
All
Phase
1
44 participants needed
1 Location
Brief description of study
The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) breast cancer and BRCA1 or BRCA2 mutations.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: ['Metastatic Breast Cancer','Locally Advanced Breast Cancer','Advanced Breast Cancer','BRCA2 Mutation','BRCA1 Mutation']
-
Age: 18 years - 99 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 831383
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
